Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritonavir effect on erlotinib pharmacokinetics
NL-OMON49212Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of erlotinib and ritonavir in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Primary endpoint: Effect of ritonavir on erlotinib pharmacokinetics. Started Sep 2019; status: active, not recruiting.
02
Drugs
erlotinibritonavir
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49212.